Eribaxaban

Identification

Name
Eribaxaban
Accession Number
DB06920
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
5FCH6YDY7Z
CAS number
536748-46-6
Weight
Average: 484.907
Monoisotopic: 484.131361124
Chemical Formula
C24H22ClFN4O4
InChI Key
QQBKAVAGLMGMHI-WIYYLYMNSA-N
InChI
InChI=1S/C24H22ClFN4O4/c1-34-18-13-21(30(14-18)24(33)27-16-7-5-15(25)6-8-16)23(32)28-20-10-9-17(12-19(20)26)29-11-3-2-4-22(29)31/h2-12,18,21H,13-14H2,1H3,(H,27,33)(H,28,32)/t18-,21-/m1/s1
IUPAC Name
(2R,4R)-N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1,2-dihydropyridin-1-yl)phenyl]-4-methoxypyrrolidine-1,2-dicarboxamide
SMILES
[H][[email protected]@]1(CN(C(=O)NC2=CC=C(Cl)C=C2)[[email protected]]([H])(C1)C(=O)NC1=CC=C(C=C1F)N1C=CC=CC1=O)OC

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UCoagulation factor XNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11634458
PubChem Substance
99443391
ChemSpider
9809202
BindingDB
50266770
ChEMBL
CHEMBL476186
HET
230
PDB Entries
2phb

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00717 mg/mLALOGPS
logP3.35ALOGPS
logP3.02ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)11.46ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.98 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity128.79 m3·mol-1ChemAxon
Polarizability47.29 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.996
Blood Brain Barrier+0.8529
Caco-2 permeable-0.5814
P-glycoprotein substrateSubstrate0.6932
P-glycoprotein inhibitor IInhibitor0.5161
P-glycoprotein inhibitor IINon-inhibitor0.7978
Renal organic cation transporterNon-inhibitor0.7211
CYP450 2C9 substrateNon-substrate0.7229
CYP450 2D6 substrateNon-substrate0.8361
CYP450 3A4 substrateSubstrate0.6764
CYP450 1A2 substrateNon-inhibitor0.7626
CYP450 2C9 inhibitorNon-inhibitor0.5337
CYP450 2D6 inhibitorNon-inhibitor0.9138
CYP450 2C19 inhibitorNon-inhibitor0.531
CYP450 3A4 inhibitorNon-inhibitor0.8565
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5361
Ames testNon AMES toxic0.7191
CarcinogenicityNon-carcinogens0.8675
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4452 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8511
hERG inhibition (predictor II)Inhibitor0.6807
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Proline and derivatives
Alternative Parents
Alpha amino acid amides / N-phenylureas / Anilides / Pyrrolidinecarboxamides / N-arylamides / Pyridinones / Chlorobenzenes / Fluorobenzenes / Dihydropyridines / Aryl chlorides
show 13 more
Substituents
Proline or derivatives / Alpha-amino acid amide / N-phenylurea / Anilide / Pyrrolidine carboxylic acid or derivatives / Pyrrolidine-2-carboxamide / Pyrrolidine-1-carboxamide / N-arylamide / Chlorobenzene / Dihydropyridine
show 33 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Details
1. Coagulation factor X
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:17 / Updated on December 01, 2017 15:43